#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14338	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2461	715.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1633	1633	C	907	C,G	906,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24172	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4052	744.8	0	.	n	.	0	T695C	SNP	695	695	T	1292	1292	C	885	C,T,A,G	880,2,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24172	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4052	744.8	0	.	n	.	0	G1337A	SNP	1337	1337	G	1934	1934	A	966	A	966	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24172	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4052	744.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2568	2568	C	850	C,T	849,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24172	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4052	744.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2642	2642	A	836	A,C	835,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24172	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4052	744.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3194	3194	C	848	C,A,T	845,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_L_00516	folP.WHO_L_00516	1	1	27	2046	folP	855	855	100.0	folP.l15.c4.ctg.1	2109	121.2	1	SNP	p	R229S	0	.	.	685	687	CGC	1272	1274	CGC	215;214;217	C;G,A;C	215;213,1;217	folP.WHO_L_00516:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4744	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3980	148.9	1	SNP	p	S91F	0	.	.	271	273	TCC	894	896	TCC	166;167;167	T;C;C,A	166;167;166,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4744	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3980	148.9	1	SNP	p	D95N	0	.	.	283	285	GAC	906	908	GAC	174;173;174	G;A;C	174;173;174	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4744	gyrA	2751	2751	99.89	gyrA.l15.c4.ctg.1	3980	148.9	1	SNP	p	D95G	0	.	.	283	285	GAC	906	908	GAC	174;173;174	G;A;C	174;173;174	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	1938	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1862	129.9	1	SNP	p	G45D	1	.	.	133	135	GAC	801	803	GAC	223;226;229	G,T;A;C	222,1;226;229	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1066	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1403	94.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	4526	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3607	156.8	1	SNP	p	D86N	0	.	.	256	258	GAC	865	867	GAC	176;176;175	G;A;C	176;176;175	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	27	4526	parC	2304	2304	99.83	parC.l15.c4.ctg.1	3607	156.8	1	SNP	p	S88P	0	.	.	262	264	TCC	871	873	TCC	179;181;180	T;C,T;C,A,G	179;180,1;178,1,1	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4056	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3167	160.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1795	1797	GGC	222;221;223	G,A;G;C	220,2;221;223	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2908	163.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1495	1497	GCA	217;216;217	G,T;C;A	216,1;216;217	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2908	163.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1498	1500	ATC	214;214;214	A;T;C	214;214;214	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2908	163.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1510	1512	GTG	211;212;214	G;T;G	211;212;214	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2908	163.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1510	1512	GTG	211;212;214	G;T;G	211;212;214	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2908	163.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2014	2016	ACC	218;222;222	A;C;C	218;222;222	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2908	163.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2068	2070	GCG	196;192;191	G;C,G;G	196;191,1;191	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2908	163.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2068	2070	GCG	196;192;191	G;C,G;G	196;191,1;191	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2908	163.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2191	2193	GGC	224;220;220	G;G;C,G	224;220;219,1	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2908	163.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2200	2202	GGC	221;224;221	G;G;C	221;224;221	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3816	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2908	163.9	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2218	2220	CTG	220;220;219	C;T;G	220;220;219	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	5068	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3706	170.9	1	SNP	p	L421P	1	L421P	NONSYN	1261	1263	CTG	1930	1932	CCG	224;223;222	C;C;G	224;223;222	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2174	porA	1146	1146	99.83	porA.l15.c17.ctg.1	2469	110.0	0	.	p	.	0	S22G	NONSYN	64	66	AGC	743	745	GGC	167;165;162	G;G;C	167;165;162	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2174	porA	1146	1146	99.83	porA.l15.c17.ctg.1	2469	110.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	925	925	C	172	C	172	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	188	90.62	porB1a.l6.c30.ctg.1	1450	20.4	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1273	1275	AAT	10;10;10	A;A;T	10;10;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	188	90.62	porB1a.l6.c30.ctg.1	1450	20.4	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1276	1278	AAT	9;9;9	A;A;T	9;9;9	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	188	90.62	porB1a.l6.c30.ctg.1	1450	20.4	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1288	1290	GTT	7;7;7	G;T;T	7;7;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	188	90.62	porB1a.l6.c30.ctg.1	1450	20.4	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1300	1302	GCG	7;7;7	G;C;G	7;7;7	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	188	90.62	porB1a.l6.c30.ctg.1	1450	20.4	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1323	1325	GTA	4;4;4	G;T;A	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	188	90.62	porB1a.l6.c30.ctg.1	1450	20.4	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1335	1335	G	5	G	5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	257	90.27	porB1a.l6.c30.ctg.2	394	13.6	0	.	p	.	0	E246K	NONSYN	736	738	GAA	9	11	AAA	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	257	90.27	porB1a.l6.c30.ctg.2	394	13.6	0	.	p	.	0	S271T	NONSYN	811	813	TCG	84	86	ACT	30;30;30	A;C;T	30;30;30	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	257	90.27	porB1a.l6.c30.ctg.2	394	13.6	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	90	92	GAT	30;30;30	G;A;T	30;30;30	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	257	90.27	porB1a.l6.c30.ctg.2	394	13.6	0	.	p	.	0	D274S	NONSYN	820	822	GAT	93	95	AGT	30;30;30	A;G;T	30;30;30	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	257	90.27	porB1a.l6.c30.ctg.2	394	13.6	0	.	p	.	0	D276N	NONSYN	826	828	GAT	99	101	AAC	30;30;30	A;A;C	30;30;30	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	257	90.27	porB1a.l6.c30.ctg.2	394	13.6	0	.	p	.	0	N277H	NONSYN	829	831	AAC	102	104	CAC	30;30;30	C;A;C	30;30;30	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	257	90.27	porB1a.l6.c30.ctg.2	394	13.6	0	.	p	.	0	R307E	NONSYN	919	921	AGA	192	194	GAA	2;2;2	G;A;A	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	257	90.27	porB1a.l6.c30.ctg.2	394	13.6	0	.	p	.	0	T311A	NONSYN	931	933	ACA	204	206	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	257	90.27	porB1a.l6.c30.ctg.2	394	13.6	0	.	p	.	0	E312D	NONSYN	934	936	GAA	207	209	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	257	90.27	porB1a.l6.c30.ctg.2	394	13.6	0	.	p	.	0	F314I	NONSYN	940	942	TTC	213	215	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	257	90.27	porB1a.l6.c30.ctg.2	394	13.6	0	.	p	.	0	A316S	NONSYN	946	948	GCG	219	221	TCG	2;2;2	T;C;G	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	257	90.27	porB1a.l6.c30.ctg.2	394	13.6	0	.	p	.	0	V318A	NONSYN	952	954	GTC	225	227	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	257	90.27	porB1a.l6.c30.ctg.2	394	13.6	0	.	p	.	0	G319S	NONSYN	955	957	GGC	228	230	AGC	3;3;3	A;G;C	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	257	90.27	porB1a.l6.c30.ctg.2	394	13.6	0	.	p	.	0	G320A	NONSYN	958	960	GGT	231	233	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	516	324	porB1a	984	257	90.27	porB1a.l6.c30.ctg.2	394	13.6	0	.	p	.	0	G322V	NONSYN	964	966	GGT	237	239	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2786	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	2147	161.6	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	922	924	AAG	246;247;249	A;A;G,T	246;247;248,1	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2786	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	2147	161.6	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	991	993	CAA	254;258;256	C;A,C;A	254;257,1;256	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2786	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	2147	161.6	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1198	1200	GAT	236;236;235	G;A;T	236;236;235	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2786	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	2147	161.6	0	.	p	.	0	H213G	NONSYN	637	639	CAT	1201	1203	GGT	234;235;234	G;G;T	234;235;234	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2786	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	2147	161.6	0	.	p	.	0	Q214H	NONSYN	640	642	CAA	1204	1206	CAT	231;231;231	C;A;T	231;231;231	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2786	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	2147	161.6	0	.	p	.	0	V215T	NONSYN	643	645	GTT	1207	1209	ACT	230;226;225	A;C;T	230;226;225	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2786	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	2147	161.6	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1216	1218	ATG	230;230;229	A;T;G	230;230;229	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2786	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	2147	161.6	0	.	p	.	0	R257T	NONSYN	769	771	AGG	1333	1335	ACG	208;211;209	A;C;G,T	208;211;208,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2786	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	2147	161.6	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1339	1341	GTT	202;202;202	G,A,T;T,C;T	199,2,1;201,1;202	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2786	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	2147	161.6	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1453	1455	AAC	237;235;235	A,G;A;C	236,1;235;235	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2786	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	2147	161.6	1	SNP	p	A121D	1	.	.	361	363	GAC	925	927	GAC	251;252;251	G;A;C	251;252;251	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2786	porB1b	1047	1047	98.57	porB1b.l6.c17.ctg.1	2147	161.6	1	SNP	p	D121N	0	.	.	361	363	GAC	925	927	GAC	251;252;251	G;A;C	251;252;251	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9484	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5326	222.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1466	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1625	112.5	1	SNP	p	V57M	1	.	.	169	171	ATG	846	848	ATG	248;249;250	A;T,C;G	248;248,1;250	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
